Abstract

Triptans generally have a low potential for drug interactions, with pharmacodynamic interactions likely to be of greater clinical significance than pharmacokinetic interactions. The most notable pharmacodynamic interactions include additive vasoconstrictor effects (e.g. with concomitant ergots) and serotonin syndrome (e.g. with concomitant selective serotonin reuptake inhibitors).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.